#6 - Editas Medicine (NASDAQ:EDIT)
A significant number of small-cap stocks are found in the biotechnology sector. That brings us to Editas Medicine Inc. (NASDAQ: EDIT), a clinical-stage company in the intriguing field of gene editing. The company’s lead therapy, EDIT-301, uses CRISPR technology to treat genetic disorders. It's currently in clinical trials for sickle cell disease and beta-thalassemia.
On the homepage of the company’s website is the question: “What if we could repair broken genes?” If you’re a long-term investor and you knew a company was going to have a therapy to do just that, you would buy it hand over fist. Imagine the ability to treat genetic-based diseases by editing a patient’s gene sequence.
But the other side of that coin is that there are no guarantees that the therapy will get approved. And even if it does, there are regulatory hurdles to climb with insurance companies.
You’ll want to follow the analysts on this one, and they are bullish on EDIT stock with a price target of $9.08—more than 200% above the price as of November 13.
About Editas Medicine
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Read More - Current Price
- $2.77
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $9.08 (227.9% Upside)
